RbM Data reveals: Site screening Due Diligence improves patient dropout and retention

A way to utilize RbM for patient retention

Clinical trial patient retention and dropout continues to be an issue amongst biopharmaceutical sponsors, as patient dropouts minimize the statistical power of clinical trial data, requiring study teams to enroll additional patients. This outcome not only expends project management and patient enrollment resources, but also causes study timeline slippage, and increases the costs associated with developing additional investigational medical product.

Read more online
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /